| Issue Date | Title | Author(s) |
| 1 | 2021 | Advantage of co-culture strategy for targeted cancer treatment and in vitro studies | Ulu, Gizem Tuğçe ; Bayram, Nazende Nur; Dinçer İşoğlu, Sevil; Baran, Yusuf |
| 2 | Sep-2008 | Bisphosphonate treatment and radiotherapy in metastatic breast cancer | Ural, Ali Uğur; Avcu, Ferit; Baran, Yusuf |
| 3 | 28-Oct-2021 | HER2-targeted, degradable core cross-linked micelles for specific and dual pH-sensitive DOX release | Bayram, Nazende Nur; Ulu, Gizem Tuğçe ; Topuzoğulları, Murat; Baran, Yusuf ; Dinçer İşoğlu, Sevil |
| 4 | Feb-2009 | Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients | Abaan, Ogan Demir; Mutlu, Pelin Kaya; Baran, Yusuf ; Atalay, Can; Gündüz, Ufuk |
| 5 | Apr-2022 | Peptıde targeted core cross-lınked mıcelles for dox delıvery to HER2 expressıng cancer cells | Bayram, Nazende Nur; Ulu, Gizem Tuğçe ; Gürdap, Seda; İşoğlu, İsmail Alper; Baran, Yusuf ; Dinçer İşoğlu, Sevil |
| 6 | Jul-2007 | Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer | Ural, Ali Uğur; Avcu, Ferit; Baran, Yusuf |
| 7 | Oct-2011 | The roles of antiapoptotic sphingosine kinase-1 and glucosylceramide genes in drug induced cell death of MCF-7 breast cancer cells | Güçlüler, Gözde; Pişkin, Özden; Baran, Yusuf |
